Heat made AZ's FluMist ineffective against swine flu; Diamyd begins diabetes jab trial;

> FluMist maker AstraZeneca ($AZN) blames heat for its vaccine's ineffectiveness against swine flu. Report

> Diamyd Medical has dosed the first patient in its Type 1 diabetes vaccine study. Release

> ACIP has recommended Merck's ($MRK) Gardasil 9 for females ages 9 to 26 and males ages 9 to 21. Release

> In a Phase I study, Themis Bioscience's Chikungunya vaccine candidate raised concentrations of neutralizing antibodies in three dose cohorts after one immunization. Release

> Targovax has appointed Øystein Soug as its new CFO. Release

And Finally... The CDC says flu vaccines were only 18% effective this season. Report (reg. req.)

Suggested Articles

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.

Experts are pushing for the introduction of J&J's vaccine in the response to the Ebola outbreak in the Democratic Republic of Congo.